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Background: Forensic psychiatric patients are often diagnosed with psychiatric disorders characterized by high levels of
impulsivity as well as comorbid substance use disorders (SUD). The combination of psychiatric disorders and SUD increases the
risk of future violence. Chronic substance abuse can lead to a structural state of disinhibition, resulting in more drug taking and
eventually loss of control over drug intake. When treating SUD, it is crucial to address high levels of impulsivity and lack of
inhibitory control.
Objective: This study set out to investigate the effects of a theta/sensorimotor rhythm (SMR) neurofeedback training protocol
on levels of impulsivity, levels of drug craving, and actual drug intake in a population of forensic psychiatric patients with a
diagnosis of SUD.
Methods: A total of 21 participants received 20 sessions of theta/SMR neurofeedback training in combination with
treatment-as-usual (TAU). Results of the intervention were compared with results from 21 participants who received TAU only.
Results: SMR magnitude showed a significant (P=.02) increase post training for patients in the neurofeedback training group,
whereas theta magnitude did not change (P=.71). Levels of drug craving as well as scores on the motor subscale of the Barratt
Impulsivity Scale-11 decreased equally for patients in the neurofeedback training group and the TAU group. Other measures of
impulsivity as well as drug intake did not change posttreatment (P>.05). Therefore, neurofeedback+TAU was not more effective
than TAU only.
Conclusions: This study demonstrated evidence that forensic psychiatric patients are able to increase SMR magnitude over the
course of neurofeedback training. However, at the group level, the increase in SMR activity was not related to any of the included
impulsivity or drug craving measures. Further research should focus on which patients will be able to benefit from neurofeedback
training at an early stage of the employed training sessions.
Trial Registration: Dutch National Trial Register: NTR5386; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5386
(Archived by WebCite at http://www.webcitation.org/6nXLQuoLl).
(JMIR Ment Health 2018;5(4):e10845)   doi:10.2196/10845
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Forensic psychiatric patients are often times diagnosed with
disorders characterized by high levels of impulsivity.
Schizophrenia, attention-deficit hyperactivity disorder (ADHD),
and cluster B personality disorders are the most common
disorders in forensic psychiatric patients [1,2]. Substance use
disorder (SUD) is a common comorbidity, occurring in about
55% to 70% of all patients [2,3].
Individuals abusing alcohol, stimulants, and opioids tend to
have higher levels of impulsivity as compared with nonabusing
controls [4]. Furthermore, impulsivity is a risk factor for the
development and maintenance of SUD [5,6]. Chronic substance
abuse can cause a structural state of disinhibition over time,
leading to permanent excessive abuse of substances [7-9]. This
state is not limited to the acute stages of substance dependency
but is also present in patients after stopping regular drug intake
[10]. Elevated levels of impulsivity are also associated with
more severe symptoms of SUD, which eventually lead to higher
levels of drug craving [11]. Once patients receive substance
abuse treatment, high levels of impulsivity can increase chances
of early relapse and premature termination of treatment [6,10].
For forensic psychiatric patients, substance use is highly
associated with the use of violence, regardless of the type of
drug used [12-14].
Important in the treatment of forensic patients with SUD is to
determine levels of impulsivity and lack of inhibitory control.
In accordance with this, common psychotherapeutic approaches
for SUD involve the adaptation of strategies that promote
conscious decision making, attention to action, and control over
behavior [9]. Despite that, relapse rates following remission of
treated SUD individuals are as high as 60% [15], stressing the
need for additional interventions.
Neurofeedback Treatment for Impulsivity and
Substance Use Disorder
In the last two decades, electroencephalographic (EEG)
neurofeedback training has shown promising results in reducing
high levels of impulsivity in patients suffering from ADHD
[16-18]. Neurofeedback training uses real-time EEG
measurements and displays this information back to the patient
[19]. EEG neurofeedback training works by enhancing or
inhibiting brain frequencies that have shown to underlie
abnormal psychological states [20]. A frequently used
neurofeedback protocol to train impulse control is the so-called
theta (3.5-7.5 Hz)/sensorimotor rhythm (SMR, 12-15 Hz)
protocol [17,21,22]. In this protocol, the magnitude of the SMR
frequency is enhanced, whereas the magnitude of the theta
frequency is inhibited.
However, the effectiveness of a theta/SMR neurofeedback
protocol on levels of impulsivity and also on symptoms of SUD
such as levels of craving and actual drug use in forensic
psychiatric patients is unclear. Only a few studies have
investigated the effects of neurofeedback training in forensic
psychiatric patients [23-26]. Therefore, investigating
effectiveness of neurofeedback training can add value to
treatment models that are currently used for this group, such as
classical psychotherapy and pharmacological treatment.
Objectives
The primary objective of this study was to examine to what
extent a theta/SMR neurofeedback training results in the
reduction of impulsivity, drug craving, and actual drug use in
a population of forensic psychiatric patients with a diagnosis
of SUD. Patients were allocated to either a
neurofeedback-training group where they received 20 sessions
of a theta/SMR neurofeedback training protocol in addition to
treatment-as-usual (TAU), or a TAU-only group. For both
groups, levels of impulsivity, as measured with the Barratt
Impulsivity Scale-11 (BIS-11) [27], and a cued Go/No-Go
reaction time task [28] were assessed. Levels of drug craving
were measured with a modified version of the Desire for Alcohol
Questionnaire (DAQ-SF) [29]. Actual drug intake was assessed
with urine or breathalyzer drug testing. Results on primary
outcome measures were compared between groups We
hypothesized that patients receiving neurofeedback
training+TAU would show reduced levels of impulsivity post
training as well as reduced levels of drug craving and drug use
in comparison with patients receiving TAU only.
Methods
Study Design and Participants
This study reports the results from a randomized controlled trial
(RCT) as described in the study by Fielenbach et al [30]. The
results of the n-of-1 clinical case series will be reported
elsewhere.
The study took place in a maximum security inpatient forensic
psychiatric center (FPC) in Groningen, the Netherlands. All
patients in this treatment facility are male criminal offenders
who were held only partially responsible for the crime they
committed due to severe mental illness, according to Dutch
jurisdiction [31]. Inclusion criteria were the presence of at least
one diagnosis of SUD according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Review
(DSM-IV-TR [32]), positive drug testing in the past 24 months
before inclusion, and sufficient knowledge of the Dutch
language to understand training instructions. All patients had
at least one comorbid axis I and/or II diagnosis. Exclusion
criteria were a state of acute psychosis, in which patients
experienced severe delusions and/or hallucinations and could
possibly become a threat to themselves or others (a diagnosis
of schizophrenia as well as disorders in the schizophrenia
spectrum [eg, schizoaffective disorder] were not considered
exclusion criteria). A comorbid diagnosis of epilepsy and visual
and/or auditory impairments, which would hamper patients’
ability to follow instructions and adhere to the neurofeedback
training, were also exclusion criteria. Medication intake was
not restricted. Patients were allowed to continue the use of
medication over the course of the study. Treatment supervisors
were informed that, during the course of the study, prescribed
medication should preferably remain stable and that a change
in type as well as dosage of medication should not be made
during the course of the study unless absolutely necessary.
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Treatment supervisors were asked to inform researchers in case
a change in type or dosage of medication did occur.
This study was conducted according to the principles of the
Declaration of Helsinki (version 59, Seoul, October 2008) and
in accordance with the Medical Research Involving Human
Subjects Act. It is ethically approved by the medical ethical
council of Brabant, the Netherlands (study number
NL46390.008.13).
Procedure
In this study, a pre-post test design was used. A power analysis
calculation for the RCT, using G*Power 3 based on a 1-tailed
alpha value of .05, a power value of 0.80, and an effect size (f)
of 0.80, yielded a recommended sample size of 21 participants
each in the control and intervention conditions.
Out of all participants that met the requirements, a random
sample was drawn and randomly assigned to 1 of the 2 study
conditions (neurofeedback training+TAU or TAU only). Patients
were approached through treatment supervisors for participation
and informed about the general outline of the study. If they
expressed interest in participating in the study, they were
approached by 1 of the researchers to explain the study design
and randomization procedure. All patients signed the informed
consent. Randomization was done by a random number
generator (see Figure 1 for an overview of patient flow through
the study).
Participants in both conditions underwent pretreatment
measurements (T0), consisting of the measurements described
below. Participants in the control group received TAU only.
TAU was different for every patient, as treatment modalities
are based on individual diagnosis and problematic behavior of
the patient as well as the cognitive ability to undergo different
treatment modalities. Examples of treatment modalities were
nonverbal therapy forms (eg, psychomotor therapy and musical
therapy) and cognitive-behavioral group therapy. After 10
weeks, participants in the control group underwent posttreatment
measurements (T1), identical to pretreatment measurements.
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram for individual randomized controlled trials of nonpharmacologic
treatments. Patients who had hair that was unsuitable for conducting electroencephalographic measurements or placement of neurofeedback electrodes,
such as dreadlocks, were excluded. For analysis of drug testing, data from 19 patients were used. SUD: substance use disorders; TAU: treatment-as-usual.
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Once pretreatment measures were completed, participants in
the intervention group started the neurofeedback training. They
received 20 neurofeedback training sessions, scheduled 2 times
a week for 10 weeks. Neurofeedback training was conducted
by a certified neurofeedback therapist. The study was not
blinded, as it was clear to patients as well as the neurofeedback
therapist which patients received the neurofeedback training.
Participants received a small financial compensation comparable
with minimum wage in the treatment facility for participation.
Neurofeedback Training Protocol
For neurofeedback training, electrode Cz was used as the
feedback electrode recorded with Ag/AgCl electrodes against
a right ear mastoid reference and a FPz ground electrode.
Neurofeedback was applied as implemented in the Brainmarker
software engine (BrainMarker Device, Brainmarker BV Gulpen).
A theta/SMR protocol was used, in which SMR (12-15 Hz)
should be enhanced and theta (3.5-7.5 Hz) should be inhibited.
If excess high beta (20-32 Hz) or delta (0.5-3.5 Hz) was
detected, these frequency bands were inhibited as well, with a
maximum of 3 frequency bands being trained in each session.
Patients were shown simple video games and instructed to find
the most successful strategy to make the main character of the
video game move. A movie-based neurofeedback paradigm was
given as well, where patients had to stop black curtains from
appearing over the computer monitor. The software provided
visual positive feedback for increasing SMR magnitude and
decreasing theta magnitude. Each round (or trial) of video games
lasted 60 seconds, with short breaks in between rounds (trials).
Movie-based feedback lasted 90 seconds at a time. The switch
between video- and movie-based feedback was done to make
neurofeedback more fun and less tiring, as choice of video
games provided within the software was limited, as well as very
simplistic. For each patient, about 10 rounds of video
game-based feedback were employed. As for movie-based
feedback, about 10 to 15 rounds were employed. Neurofeedback
training lasted for approximately 45 min, including preparation
and cleanup.
Feedback thresholds were adjusted manually whenever
participants were able to increase or decrease the desired
frequency bands for 80% of the time. Participants were verbally
encouraged to try to move the main character in the video game
as much as possible as well as to keep the monitor free from
the curtains during video-based feedback and not just stare at
the screen (see Figure 2 for an impression of one of the
neurofeedback games). After all training sessions were




A 5 min 21-channel EEG resting-state measurement with eyes
closed was conducted with Nexus-32 hardware and Biotrace
software (MindMedia BV). EEG measurements were collected
from 19 standard 10/20 positions [33] and the right and left
mastoids with a sampling rate of 512 samples per second. The
right mastoid served as the online reference. Flat type electrodes
were placed above and below the left eye and at the outer canthi
of each eye to correct for vertical and horizontal eye movements.
EEG magnitude across delta (0.5-3.5 Hz), theta (3.5-7.5 Hz),
alpha (7.5-12 Hz), beta (12-20 Hz), SMR (12-15 Hz), high beta
(20-32 Hz), and gamma (32-49 Hz) frequency bands was
assessed. Magnitude changes in delta, theta, SMR, and high
beta frequency were used for analysis. For analysis,
custom-made Matlab scripts (version R2012b) were used. First,
data from the resting-state measurements were imported into
EEGLAB, bandpass filtered between 1-40 Hz, and inspected
for gross movement artifacts that were then manually removed.
Subsequently, epochs of 4 seconds length were created. Epochs
containing amplitudes exceeding ±100 μV at any scalp electrode
and/or epochs containing abnormally distributed data (ie, joint
probability or kurtosis >5 SD from expected mean values) were
rejected. From the remaining epochs, the first 40 were
transformed into FieldTrip format (version 20160620). Power
values for electrode Cz were computed using a fast Fourier
analysis with a Hanning taper as implemented in FieldTrip.
Figure 2. Impression of one of the games used for neurofeedback training using one frequency band. Participants had to try to exceed the bar above
the threshold, after which an encouraging smiley popped up on the screen, giving immediate positive reinforcement.
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Mean power values for delta, theta, SMR, and high beta
frequency bands were calculated and transferred to SPSS for
statistical analysis.
Barratt Impulsivity Scale-11
The Dutch version of the BIS-11 [27] is a 30-item self-report
questionnaire that assesses common impulsive behaviors and
preferences across 3 second-order factors: motor, attentional,
and nonplanning. An example of a BIS-11 item is “I do things
without thinking,” and items are scored across a 4-point Likert
scale ranging from “rarely/never” to “almost always/always.”
The BIS-11 is an internally consistent measure of impulsivity
among inmate populations (Cronbach alpha=. 80) [34].
Cued Go/No-Go Task
The cued Go/No-Go task is a continuous performance test
designed to measure response inhibition [28]. The task was
programmed in E-Prime (version 2.0.10.353). Participants are
instructed to respond as quickly as possible to a green square
appearing on a screen (“Go target”) but to inhibit responses to
a blue square (“No-Go target”). The test consists of 250 targets
with equal numbers of Go and No-Go targets. Each target is
preceded by either a Go or a No-Go cue, indicating the
likelihood of a Go or No-Go target to appear. The likelihood of
a correct target after a cue is manipulated with a 80/20 ratio,
with 80% being a correct cue and 20% being an incorrect cue.
Cues are presented with 4 fixed stimulus onset asynchronies
(100, 200, 300, and 400 milliseconds). The program displays
feedback about the accuracy of the response back to the
participant as well as the time (in milliseconds) it took for the
patient to respond to the target. Outcome measure is the number
of commission errors, reflecting the failure to inhibit a prepotent
response to a No-Go square. Number of commission errors in
a cued Go/No-Go task is a valid measure of impulse control in
a substance abusing population [28].
Modified Version of the Desire for Alcohol
Questionnaire Short Form
The short form of the DAQ-SF is a self-report questionnaire
that measures levels of craving for alcohol among 14 items
scored on a 7-point Likert scale (ranging from 1=strongly
disagree to 7=strongly agree). The DAQ-SF has been shown to
be a reliable measure to assess craving in a substance-dependent
population (Cronbach alpha=.70) [35]. For the purpose of this
study, items from the Dutch version of the questionnaire [29]
were modified to measure desire for drugs in general, as opposed
to being restricted to measure desire for alcohol only. An
example of a modified item is “All my tension would completely
disappear if I drank now” into “All my tension would completely
disappear if I used drugs now.” The modification was made due
to the fact that alcohol use is very rare in an inpatient setting,
whereas use of other drugs (eg, cannabis or cocaine) is more
common.
Drug Use
Scores on urine or breathalyzer drug testing were collected for
each participant. Drug testing was performed regularly for each
patient as part of treatment facility policy. Drug use was
operationalized as any positive scoring for use of illegal
substances. Illegal substances included all known drugs as well
as alcohol and nonprescribed medication used as recreational
drug consumption (eg, inhaled methylphenidate). According to
treatment facility policy, refusal to undergo drug testing was
scored as positive drug testing. To score substance abuse, the
item “substance abuse” on the risk assessment scale Historische,
Klinische, Toekomst-Revised (Historical, Clinical,
Future-Revised) was used [36,37]. This item was scored on a
5-point scale, indicating number of positive drug testing as well
as willingness to undergo drug testing. Scores ranged from 0
(no drug use whatsoever) to 4 (the patient tested positive at least
twice and also refused to undergo drug testing).
Data and Statistical Analysis
All participants who completed pre- and posttreatment measures
were included in the statistical analysis (n=42). For analysis of
drug testing, weekly reports of 2 of the patients from the control
group were not available; therefore, the analysis of drug testing
consists of data from 40 patients. All data were analyzed with
SPSS version 25 (IBM Corp).
Due to violations of statistical assumptions concerning normality
and homoscedasticity of almost all dependent variables (BIS
motor, BIS attentional, BIS total score, DAQ-SF, delta
magnitude, theta magnitude, SMR magnitude, and Cued
Go/No-Go commission errors), nonparametric tests were
employed. To test for differences between treatment conditions
pretreatment, Mann-Whitney U tests were performed for
pretreatment scores on BIS-11 total score, BIS-11 subscales
“motor,” “nonplanning,” and “attentional” as well as scores on
DAQ-SF, number of commission errors, drug testing, and mean
theta and SMR magnitude. A Wilcoxon signed-rank test was
performed to assess changes within groups between pre- and
posttreatment for all dependent variables.
A repeated-measures analysis of variance with time as
within-subject variable and treatment condition as a
between-subject variable was performed. To assess significance,
a within-groups effect size was used (eta squared [η2]). Cutoff
scores were used according to Cohen’s rules to assess whether
effect size were small (η2=0.02), medium (η2=0.13), or large
(η2=0.26) [38].
Pearson correlations were performed to test for relations between
changes in delta, SMR, high beta, and theta frequency magnitude
pretreatment versus posttreatment and all behavioral measures.
Only results significant at the .05 level will be reported.
Results
Patient Flow
Of those assessed (N=258), 52.71% of patients (136/258) were
excluded due to not fitting the inclusion criteria. Moreover, 47.3
% (122/258) of patients were eligible for participation. Those
eligible were randomly assigned to either the neurofeedback
training+TAU group (n=42) or TAU only group (n=41). Figure
1 summarizes the flow of participants throughout the study.
In total, 42 patients completed all posttreatment measurements,
of which 21 patients participated in the TAU only group and
21 patients in the neurofeedback training+TAU group. None of
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the patients in the neurofeedback training+TAU group were
able to complete training within the scheduled 10 weeks. This
was due to holidays and planning issues and also because some
patients were mentally unable to complete a training session or
caused aggressive incidents, which resulted in temporary
separation/placement on a specialized crisis unit. It sometimes
also happened that patients were unmotivated to attend a training
session. Participation in the study, therefore, lasted for an
average of 14.1 (SD 5.32) weeks per patient.
When pretreatment measurements were assessed, mean number
of months in treatment was 93.6 months (SD 67.18). The large
SD was caused by 5 patients who had already been hospitalized
for more than 200 months in the treatment facility. Participants
did not differ with regard to mean age between the
neurofeedback training+TAU group (mean 38.00, SD 9.18) and
TAU only group (mean 38.57, SD 8.41; t40=−0.22, P=.63) or
mean number of axis I and II DSM-IV-TR diagnoses
(neurofeedback training group mean 4.52, SD 1.47; TAU only
group mean 4.57, SD 1.63, t40=−0.09, P=.38) or month in
treatment before inclusion (neurofeedback training group mean
91.90, SD 61.70; TAU only group mean 95.30, SD 73.76,
t40=−0.16, P=.87; see Tables 1-3 for sample characteristics).
Baseline Differences Between Groups
A Mann-Whitney U test indicated that scores on SMR
magnitude on pretreatment measurements were significantly
higher for patients in the neurofeedback training group
(median=1) than for patients in the TAU group (median=.58),
U=131.00, P=.02, r=.35.
Differences Within Groups
Only the neurofeedback training group showed significant
effects between pre- and posttreatment scores. Within-groups
differences on the BIS-11 subscale motor (pretreatment:
median=23) showed a significant decrease posttreatment for
patients in the neurofeedback training group (median=21,
Z=2.076, P=.04, r=.45), as well as a significant decrease in
craving scores posttreatment (median=34) as measured with the
DAQ-SF (Z=2.091, P=.04, r=.46). SMR mean amplitude also
significantly increased from pretreatment (median=1) to
posttreatment (median=1.22; Z=2.068, P=.04, r=.45).
Outcome Measures
The main outcome measures are presented in Table 4. On the
primary outcome measures, results on the motor subscale of the
BIS-11 showed a significant effect for Time (F1,40=5.61, P=.02)
but not for Time x Group (F1,40=1.28, P=.28). For the drug
craving measure DAQ-SF, there was a significant effect for
Time (F1,40=6.23, P=.02) but not for Time x Group (F1,40=9.2,
P=.34). There was a significant Time x Group effect for mean
SMR magnitude (F1,40=5.47, P=.02), indicating an increase for
mean SMR magnitude in the neurofeedback training group
posttreatment. Results for drug use, mean theta magnitude, and
number of commission errors posttreatment were not significant.
Pearson correlations revealed no significant correlations (P>.05)
between the difference in SMR or theta magnitude by the end
of the training and behavioral outcome measures.
Table 1. Baseline sample characteristics (N=42).
Treatment-as-usual only groupNeurofeedback training groupSample characteristics
38.57 (26-55)38.00 (21-55)Age (years), mean (range)
95.30 (10-290)91.90 (19-248)Months in treatment at T0, mean (range)
4.6 (1-7)4.5 (2-8)Axis I and II diagnoses, mean (range)
23.77 (15-36)23.86 (15-32)Psychopathy score (PCL-Ra), mean (range)
aPCL-R: Psychopathy Checklist–Revised.
Table 2. Type of substance use diagnosis for the neurofeedback training group and the treatment-as-usual only group (N=42).





9 (42.86)5 (23. 81)Cocaine
1 (4.76)2 (9.52)Sedative
0 (0)3 (14.29)Other
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Table 3. Comorbid axis I and II diagnosis and index offense for the neurofeedback training group and the treatment-as-usual (TAU) only group (N=42).
Treatment-as-usual group, n (%)Neurofeedback training group, n (%)Comorbid axis I and II diagnosis and index offense
Comorbid axis I disorder
0 (0)2 (9.52)Pervasive developmental disordera
3 (14.29)6 (28.57)ADHDb
10 (47.62)12 (57.14)Disorders in the schizophrenia spectrum
2 (9.52)2 (9.52)Mood and anxiety disorder
1 (4.76)1 (4.76)Pedophilia
3 (14.29)2 (9.52)PTSDc
Comorbid axis II disorder
7 (33.33)8 (38.10)Antisocial personality disorder
4 (19.05)2 (9.52)Borderline personality disorder
7 (33.33)7 (33.33)Personality disorder not otherwise specified
1 (4.76)1 (4.76)Avoidant personality disorder
Index offensed
7 (33.33)9 (42.86)Homicide
4 (19.05)2 (9.52)Sexual offense
2 (9.52)1 (4.76)Arson
3 (14.29)3 (14.29)Violence
3 (14.29)4 (19.05)Threat against life
2 (9.52)2 (9.52)Theft
aPervasive developmental disorder: Autism spectrum disorder, Asperger disorder, developmental disorder not otherwise specified.
bADHD: all types of attention-deficit disorder.
cPTSD: posttraumatic stress disorder.
dIndex offense: in case of more than one index offense, the most serious one is reported, based on the classification given in the study by Nieuwenhuizen
et al [3].
Table 4. Main outcome measures of repeated measures analysis. Sample sizes were N=42, except for scores on drug use which was n=40. Significant
results are in italics.




P valueFP valueFP valueF
.03.241.45.52.41.093.0262.62 (11.5)63.33 (12.23)63.10 (10.88)67.05 (11.05)BIS-11a
.03.261.28.271.27.025.6120.95 (4.42)21.81 (4.49)21.67 (3.97)24.10 (6.24)BIS-11 motor
.02.44.60.99.00.71.1425.6 (6.03)25.3 (6.18)25.05 (.5.82)25.86 (4.21)BIS-11 nonplanning
.01.52.43.55.36.33.9616.05 (3.79)16.19 (4.06)16.38 (3.2)17.10 (3.36)BIS-11 attentional
.02.34.92.89.02.026.2339.24 (16.49)42.72 (17.48)36.38 (20.45)44.19 (17.77)DAQ-SFb
.02.34.92.211.59.59.301.14 (1.42)1.00 (1.00)1.52 (1.91)2.05 (3.44)Commission errors
.03.271.27.102.91.201.67.22 (.35).23 (.31).38 (.50).53 (.64)Drug use
.00.71.14.093.12.191.812.75 (1.72)2.54 (1.64)4.31 (3.53)3.94 (3.67)Theta
.12.025.47.0010.56.035.00.64 (.35).65 (.39)1.23 (.66)1.01 (.52)SMRc
aBIS-11: Barratt Impulsivity Scale-11.
bDAQ-SF: Desire for Alcohol Questionnaire.
cSMR: sensorimotor rhythm.
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This RCT was conducted to investigate to what extent a
theta/SMR neurofeedback training protocol in combination with
TAU is able to reduce impulsivity and symptoms of SUD in a
population of male forensic psychiatric patients residing in an
FPC. The RCT compared a neurofeedback training group of 21
patients who received neurofeedback training in addition to
TAU with a control group of 21 patients receiving TAU only.
Changes in targeted frequency bands and changes in levels of
impulsivity, drug craving, and drug intake posttreatment were
examined in patients in the neurofeedback training group and
compared with patients in the TAU only group. Results indicate
that SMR magnitude showed a significant increase posttreatment
in the neurofeedback training group, whereas theta magnitude
did not show any changes. Surprisingly, patients in the
neurofeedback training group had significantly higher SMR
magnitude pretreatment than patients in the TAU only group.
Levels of drug craving and motor impulsivity as assessed with
the BIS-11 decreased equally for patients in the neurofeedback
training group and the TAU only group. Therefore, the
combination of TAU and neurofeedback training was not more
effective than TAU only. Other measures of impulsivity and
number of drug use did not change posttreatment.
To the best of our knowledge, this is the first RCT study
investigating the effects of neurofeedback training in a
population of forensic psychiatric patients. Studies on
investigating neurofeedback training have steadily increased in
the past two decades, but neurofeedback training is rarely used
as a treatment option for forensic psychiatric patients. This could
partially be due to the fact that these patients usually present
with a variety of disorders, and research on the effects of
neurofeedback usually exclude patients with comorbid disorders
[39-42]. Furthermore, practitioners might be hesitant to employ
a treatment modality for which the efficacy in such a complex
patient population is yet to be demonstrated.
The fact that effects of neurofeedback training were not superior
to TAU only has also been observed in other studies that applied
neurofeedback in an attempt to reduce levels of impulsivity.
Bink et al [43] employed a theta/SMR protocol in children with
ADHD but found the combination of TAU and neurofeedback
as effective as TAU only. Schönenberg et al [44] also found no
superiority of a theta/beta neurofeedback training over a
meta-cognitive therapy or even a sham neurofeedback condition.
Both Bink et al [43] and Schönenberg et al [44] applied the
training in subjects with a single, well-defined disorder without
any comorbidities. Hence, it can be argued that for patients with
multiple disorders and characterized by high levels of
impulsivity, finding behavioral improvements due to
neurofeedback training may be even more difficult.
The results of this study also raise the question as to how
participants’ failure to decrease theta activity over the course
of the training is associated with the lack of behavioral
improvements posttreatment. To date, there are no clear
guidelines about how many neurofeedback training sessions are
actually needed to achieve significant treatment effects; it is
possible that improvements in the theta frequency band could
have been achieved with more sessions. Bink et al [43] found
that adolescents with ADHD were better able to suppress theta
frequency by the end of the training sessions than at the
beginning of neurofeedback training. In the study by Bink et al
[43], 37 sessions were employed, but they still did not observe
an effect of the neurofeedback training in the reduction of
impulsivity. It may be the case that the 20 sessions of
neurofeedback provided in this study simply were not enough
for this patient group to learn to regulate the theta frequency
band. However, patients’ inability to adhere to the training
schedule of 2 neurofeedback sessions a week might be indicative
of the feasibility of a neurofeedback protocol that employs even
more sessions. Throughout this study, it was difficult to keep
patients engaged in the study. Although the specific patient
population at hand is difficult to engage in treatment no matter
which treatment is applied, the fact that none of the patients in
the neurofeedback training group were able to attend 2 sessions
a week is concerning. This was partially due the fact that
neurofeedback software is still in its infancy and options
concerning the employed training methods are limited. In most
cases, the implemented video games are quite simplistic. A lot
of patients reported that they found the intervention dull, which
most likely was of negative influence on treatment motivation.
An abbreviated protocol might be better suited for this patient
population in terms of keeping patients engaged in the training.
In addition, as results of this study showed no significant relation
between patient’s reduction in theta magnitude and behavioral
outcome measures, it remains unclear as to whether (more)
improvements in theta activity regulation can lead to (better)
clinical improvements at the behavioral level. However, patients
did manage to increase SMR magnitude posttreatment. It is
possible that the SMR frequency band is easier to regulate with
neurofeedback training. In a recent study by Fielenbach et al
[45], which focused on whether forensic psychiatric patients
are actually able to learn to regulate cortical activity through
neurofeedback training, more patients were able to
systematically increase SMR activity as opposed to reducing
theta activity. In a study by Doppelmayr and Weber [46], healthy
participants were better able to regulate SMR activity than to
change the theta/beta ratio, and a recent study by Janssen et al
[39] showed that adolescents were not able to inhibit their theta
frequency but did manage to increase beta activity.
It is unclear why patients in the neurofeedback training group
showed higher pretreatment SMR magnitude than patients in
the TAU only group, as patients’ distribution over groups was
random. However, previous studies with healthy participants
have suggested that pretreatment SMR magnitude is a predictor
of participants ability to increase of SMR magnitude over the
course of neurofeedback training [47-50]. Possibly, the higher
pretreatment levels of SMR magnitude contributed to the finding
that patients did manage to increase SMR magnitude over the
course of training.
Recently, quantitative electroencephalography (QEEG)-guided
neurofeedback protocols are increasingly implemented in clinical
practice. With these protocols, pretreatment EEG deviations are
first assessed and the applied neurofeedback protocol then
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focusses on treating these EEG deviations, as opposed to
applying a standard neurofeedback protocol to all participants.
Although there is also discussion in the literature about the use
of QEEG approach of neurofeedback treatment (eg, Johnson
and Bodenhamer-Davis [51]), this approach fits with the rise
of personalized medicine in the past decade, where a treatment
approach tailored to the individual is applied rather than a
one-size-fits-all approach. Especially for forensic psychiatric
patients, usually presenting with a wide range of comorbidities,
manifesting through various deviations in EEG-frequencies,
this might be a more suitable approach than applying
standardized neurofeedback protocols.
Limitations and Recommendations for Future Studies
Patients taking prescription medication were allowed to keep
taking these medications during the course of the study. Given
the special setting where this study was conducted, limiting
medication intake would have severely hampered patient
recruitment. However, almost all types of medication commonly
prescribed for forensic psychiatric patients tend to have effects
on EEG frequencies. Several studies have shown that stimulant
medication such as methylphenidate normalizes EEG
frequencies and may lead to a reduction of theta band magnitude
and an increase in low beta bands magnitude [49,50]. Medication
for disorders in the schizophrenia spectrum, such as clozapine,
have been shown to increase theta activity (Hyun et al [52]). It
is very well possible that the results of this study were, to some
extent, influenced by the type and/or dosage of patients’
medication. A theta/SMR neurofeedback protocol might not
lead to significant changes in EEG-frequencies when these
frequency bands are already normalized due to use of
medication, although this remains speculative. In this study,
changes in medication were insufficiently tracked during the
course of the study. Future studies should investigate the effects
of medication on the EEG spectrum more closely before
applying neurofeedback or should at least control for medication
intake during the analysis to achieve more conclusive results.
Another limitation concerning medication is the fact that some
medication, such as aripiprazole, is known to have positive
effects on levels of craving (Beresford et al [53]), which could
have influenced the results on the craving questionnaire
DAQ-SF.
Moreover, with the patient sample of this study, there was
heterogeneity concerning substances used by study participants.
This is quite common in patients with SUD, as many patients
are polydrug abusers. This may have altered the results and
potentially influenced the effects of neurofeedback in these
patients. In addition, we followed treatment facility policy,
where a refusal to undergo drug testing is scored as having a
positive drug testing. There is no way to be certain that patients
who refused to undergo drug testing did, in fact, use illicit
substances. However, given our clinical experience, patients
refusal to undergo drug testing usually lies in the fact that they
have relapsed in drug use, as patients have no reason to refuse
to undergo drug testing other than fear of having drug use
exposed. Refusal to undergo drug testing will result in the loss
of privileges, so that refusing to undergo drug testing comes at
a reasonable cost to patients.
In addition, the fact that none of the patients in the
neurofeedback training group were able to complete the training
in the scheduled amount of time could have influenced the
results. Possibly, results achieved in terms of enhancing or
inhibiting EEG frequencies were lost in between sessions
because patients were not able to follow the scheduled training
sessions. To date, there is no conclusive research indicating the
ideal number of neurofeedback training sessions or the most
beneficial interval time in between training sessions. For this
study, adhering to a very strict training schedule, where patients
would have been excluded from further participation whenever
they missed a session, would have resulted in a very high
number of dropouts and consequently in lower power of the
results found. Nonetheless, the failure of patients’ adherence to
the schedule could have been of influence on the study results.
Another limitation of this study is that a sham-neurofeedback
control group was not added to the study. Although some authors
challenge the use of a sham neurofeedback condition [54], as
even a sham-based neurofeedback training can lead to treatment
outcomes, it could have been useful to add a waiting list group
as an untreated control condition.
Future studies should also investigate whether results in terms
of patients’ ability to increase or decrease their frequency
magnitude vary when manually adjusted thresholds are applied
versus when automatically adjusted thresholds are applied.
Manually adjusted thresholds are subject to the expertise of the
neurofeedback trainer; therefore, they are also subject to, for
example, inattention of the trainer. Automatically adjusted
thresholds provide a more objective way of adjusting thresholds,
which might be better suitable for scientific purposes.
Conclusions
This study highlights that more research is needed to assess the
efficacy of a theta/SMR neurofeedback protocol for the
reduction of impulsivity, drug craving, and drug intake in
forensic psychiatric patients with substance abuse problems.
Results showed that patients were unable to learn the whole
neurofeedback protocol as they did not succeed in reducing
theta activity. Future research should focus on assessing which
patients will be able to benefit from neurofeedback training at
an early stage of the employed training sessions. Given that
neurofeedback training is often times applied in vulnerable
patient populations such as children, adolescents, and patients
with severe mental illness or addiction, it can be considered
unethical to enroll these patients in any treatment with the
knowledge that it will most likely not lead to beneficial
outcomes in terms of reduction of clinical symptoms. Weber et
al [55] have made an important start with their research on
predicting successful learning of SMR neurofeedback in healthy
participants. This research needs to be extended to clinical
populations.
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